C - Chemistry – Metallurgy – 07 – D
Patent
C - Chemistry, Metallurgy
07
D
C07D 217/24 (2006.01) A61K 31/472 (2006.01) C07D 401/06 (2006.01) C07D 403/06 (2006.01) C07D 403/12 (2006.01) C07D 409/12 (2006.01) C07D 413/12 (2006.01) C07D 495/04 (2006.01)
Patent
CA 2421819
The present invention concerns certain isoquinolinone compounds and their utility as inhibitors of voltage-dependent potassium channels or currents, such as Kv1.5 and IKur, that could serve as targets for the treatment of cardiac arrhythmias especially atrial arrhythmias. The present invention also provide a method for treating or preventing conditions which respond to the inhibition of potassium channels or currents, such as cardiac arrhythmias and more especially atrial arrhythmias. The present invention further includes pharmaceutical formulations and a process of making a pharmaceutical composition comprising a compound of certain isoquinolinone or its pharmaceutically acceptable salts, hydrates, solvates, crystal forms, and stereoisomers thereof, and a pharmaceutically acceptable carrier.
L'invention concerne certains composés d'isoquinolinone et l'utilisation de ceux-ci comme inhibiteurs des canaux ou des courants potassiques dépendants de la tension, tels que K¿v?1.5 et I¿Kur? pouvant servir de cibles pour le traitement d'arythmies cardiaques, notamment des arythmies auriculaires. L'invention concerne également une méthode de traitement ou de prévention d'états répondant à l'inhibition des canaux ou des courants potassiques, tels que des arythmies cardiaques et plus précisément des arythmies auriculaires. L'invention concerne en outre des préparations pharmaceutiques et un procédé de fabrication d'une composition pharmaceutique renfermant un composé d'une certaine isoquinolinone ou des sels, des hydrates, des solvates, des formes cristallines et des stéréoisomères acceptables sur le plan pharmaceutique de celle-ci, ainsi qu'un excipient acceptable sur le plan pharmaceutique.
Claremon David A.
Liverton Nigel J.
Mcintyre Charles J.
Merck & Co. Inc.
Merck Sharp & Dohme Corp.
Norton Rose Or S.e.n.c.r.l. S.r.l./llp
LandOfFree
Isoquinolinone potassium channel inhibitors does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Isoquinolinone potassium channel inhibitors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Isoquinolinone potassium channel inhibitors will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-1541832